Figure 3.
(A) Plasma Cmax versus dose following a 1-h infusion of eribulin on day 1; (B) Plasma area under the concentration-time curve (AUC)(0–∞) versus dose following a 1-h infusion of eribulin on day 1; (C) Plasma concentration versus time profile for the 1.0 mg/m2 treatment group (n = 9) [50].
